WellCell Holdings Co., Limited released an update on 17 April 2026 detailing the composition of its seven-member Board and the structure of its four specialised committees.
The Board now comprises three Executive Directors, one Non-executive Director and three Independent Non-executive Directors. Chairman Qian Fenglei heads the Executive team alongside Jia Zhengyi and Zhang Xiaolong. Lin Qihao serves as the sole Non-executive Director. Independent oversight is provided by Wong Che Man Eddy, Dan Xi and Chan Wai Dune.
Committee leadership is concentrated in the hands of Independent Non-executive Director Wong Che Man Eddy, who chairs the Audit, Remuneration and Nomination Committees while also serving as a member of the Investment Committee. Zhang Xiaolong leads the Investment Committee, with Chan Wai Dune acting as a member across all four committees. Dan Xi holds member positions on the Audit, Remuneration and Nomination Committees.
The disclosure confirms that the Executive Directors currently hold no positions on any of the four committees, underscoring WellCell’s separation of management and oversight functions in line with corporate-governance best practices. The announcement did not report any additional changes to board size, tenure or remuneration.
Comments